Gilead settles patent litigation for Descovy, Vemlidy, Odefsey; generic licenses begin 2031-2032

GILEAD SCIENCES, INC.

Agreements with Lupin, Apotex, Macleods, Hetero, Cipla resolve patent challenges for HIV drugs.
License for Descovy and Vemlidy begins Oct 31, 2031; for Odefsey begins Jan 31, 2032, with earlier entry possible.
Agreements filed with FTC and DOJ; dismissals filed in Delaware district court.
Settlement removes litigation uncertainty but establishes generic entry timeline for key HIV portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.